HZB coordinates European collaboration to develop active agents against Corona
The MX team at BESSY II specialises in analysing protein structures. This can also accelerate the development of drugs against COVID-19. © HZB
X-ray structure analysis at BESSY II enables the systematic testing of many thousands of molecules that could inhibit the reproduction and virulence of SARS-CoV2 viruses. Now, a team at HZB with partners from Austria and the Czech Republic has set up the NECESSITY project to investigate more than 8000 compounds in a high-throughput procedure and develop active agents against COVID-19.
The COVID-19 pandemic is far from over. Despite the rapid development of vaccines, it is not possible, for various reasons, to give everyone lasting protection through vaccination quickly enough. But so far, there are hardly any effective drugs for patients severely affected by COVID-19. Therapy is mainly limited to the administration of steroid drugs to control the immune reaction and artificial respiration.
Researchers around HZB-scientist Dr. Christian Feiler have initiated a three-party European research study termed NECESSITY, led by project partner Prof. Dr. Klaus Scheffzek (Med. University Innsbruck, Austria). Their goal is to investigate detailed interactions between Sars-CoV-2 proteins and chemical compounds developed and provided by Dr. Vladimír Kryštof (Palacký University Olomouc, the Czech Republic), using structural and biochemical approaches. X-ray structure analysis at BESSY II enables the systematic testing of many thousands of molecules that could inhibit the reproduction and virulence of SARS-CoV2 viruses. This research is funded by the Austrian Science Fund (FWF), the German Research Foundation (DFG), and the Czech Science Foundation (GACR).
At the light source BESSY II, which is operated by HZB, the structural analysis of macromolecules provides a fantastic tool to accelerate the development of effective substances against the SARS-CoV2 virus. The three-dimensional structure of the so-called viral main protease was determined at BESSY II for the first time at the beginning of 2020. This enzyme is indispensable for virus replication. However, it is not sufficient to investigate this one target, which is why several viral target proteins are being addressed in the NECESSITY project. The consortium will explore more than 8000 compounds at the MX-beamlines of BESSY II in a high-throughput procedure and identify substances from them that could dock to the main protease of SARS-CoV-2 or other target proteins. These drug-like candidates originate from a unique library generated and collected by Dr. Vladimír Kryštof, Palacký University Olomouc. All compounds are either already approved for the treatment of other diseases or are in various clinical phases. If hits were to come out of this, it would be possible to develop drugs against COVID-19 remarkably quickly. Prof. Dr. Klaus Scheffzek and his team at the Medical University in Innsbruck can investigate the hit compounds in detail using biophysical methods and initiate the first virological studies. Prof. Dr. Christian Drosten, Director of the Institute of Virology at Charité Berlin, and other experts are also on board as advisors and partners.
"In the NECESSITY project, we bring together expertise from different fields," says Feiler. "Together, we have planned a very efficient interdisciplinary workflow to identify antiviral substances that can be used as effective drugs against COVID-19 and beyond as quickly as possible."
The project is funded by the German Research Foundation and the corresponding funding organizations in Austria and the Czech Republic for 36 months with almost 800,000 Euros.
- Magnetic imaging: Micro-flowers increase the local magnetic fieldMaterials with magnetic nanostructures have many potential applications such as in spintronics. To explore such materials, nanoscale magnetic-sensitive imaging techniques are very useful, but up to now only weak magnetic fields could be applied during the imaging process. Now an international collaboration led by Dr. Sergio Valencia, HZB, has developed an approach that overcomes this limitation. The team designed tiny magnetic flux concentrators (MFCs), into which the sample is placed. The geometry of the MFCs resembles a flower with a number of petals which focus the applied magnetic field into its center. This greatly expands the magnetic field range available during imaging, and so the range of magnetic systems that can be investigated. The micro-flowers, enhancing magnetic fields locally, can find application in different nanometric magnetic microscopy techniques.
- CIGS-perovskite tandem cell achieves record efficiency of 25.5 %A Berlin-based team from HZB and Center for the Science of Materials Berlin (CSMB) at the Humboldt-Universität zu Berlin has set a new record for a tandem solar cell. Using a combination of a CIGS semiconductor layer and perovskite, along with several optimised intermediate layers, they were able to convert 25.5% of sunlight into electrical energy. The previous record for this combination of materials and this size of cell stood at 24.6%. The new record has been certified and is visible in the prestigious Solar Cell Efficiency Tables (the "Green Tables"), which serve as the definitive ledger for the global photovoltaic community.
- Disorder creates new properties in compound semiconductorsAn international research team has demonstrated that the intrinsic disorder of the compound semiconductor CuInSnS₄ can be exploited to influence its optical properties. While the atomic vibrations also sense the local disorder, their response is averaged over many different local environments and therefore appear isotropic, as expected for a cubic crystal. In contrast, the optical excitations, known as excitons, are much more sensitive to the local arrangement of atoms. Surprisingly, they show a direction-dependent optical response even though the average crystal structure is cubic. These findings shed new light on the relationship between disorder and material properties, opening up new options for targeted 'disorder engineering' in optoelectronic and photocatalytic devices.